CN103142526A - Dropping pills containing colloidal bismuth pectin - Google Patents

Dropping pills containing colloidal bismuth pectin Download PDF

Info

Publication number
CN103142526A
CN103142526A CN2013100926509A CN201310092650A CN103142526A CN 103142526 A CN103142526 A CN 103142526A CN 2013100926509 A CN2013100926509 A CN 2013100926509A CN 201310092650 A CN201310092650 A CN 201310092650A CN 103142526 A CN103142526 A CN 103142526A
Authority
CN
China
Prior art keywords
drop pill
colloidal bismmth
bismmth pectin
clathrate
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2013100926509A
Other languages
Chinese (zh)
Other versions
CN103142526B (en
Inventor
王明刚
任莉
陈阳生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Guoxin Pharmaceutical Co ltd
Original Assignee
Qingdao Chia Tai Haier Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingdao Chia Tai Haier Pharmaceutical Co Ltd filed Critical Qingdao Chia Tai Haier Pharmaceutical Co Ltd
Priority to CN201310092650.9A priority Critical patent/CN103142526B/en
Publication of CN103142526A publication Critical patent/CN103142526A/en
Application granted granted Critical
Publication of CN103142526B publication Critical patent/CN103142526B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The application relates to dropping pills, and in particular relates to dropping pills containing colloidal bismuth pectin clathrate compounds.

Description

The drop pill that comprises colloidal bismmth pectin
Technical field
The application relates to a kind of drop pill, particularly, is the drop pill that comprises the colloidal bismmth pectin clathrate.
Background technology
Drop pill has the following characteristics: 1, equipment simple, easy to operate, be beneficial to labor protection, process cycle is short, productivity ratio is high; 2, process conditions are easy to control, steady quality, and dosage is accurate, and heated time is short, after easily oxidation and the volatile medicine of tool are dissolved in substrate, can increase its stability; 3, to hold the liquid drug amount large for substrate, therefore liquid drug is solidified; 4, the drop pill with the solid dispersion technology preparation has the characteristics rapid, that bioavailability is high that absorb.
Clathrate has the following advantages: cover bad stink, reduce zest; Increase drug dissolution and bioavailability; Improve medicine stability.
Colloidal bismmth pectin is a kind of novel macromolecule bismuth, and molecular weight is large, and is colloid-stabilised, be difficult to be absorbed by the body, and the untoward reaction and the side effect that easily cause without similar drugs.Be mainly used in treating chronic gastritis.Colloidal bismmth pectin with the biomacromolecule pectic acid replaced in traditional bismuth preparation in, the micromolecule acid group, improved colloid property, mucosa is stronger; Observe under gastroscope, the colloidal bismmth pectin gel more trends towards being deposited on ulcer and hemorrhage mucomembranous surface, has fabulous selection adhesiveness.Colloidal bismmth pectin is mainly used in gastric and duodenal ulcers, also can be used for the treatment of chronic superficial gastritis, chronic atrophic gastritis and digestive tract hemorrhage.
Summary of the invention
The present invention has invented colloidal bismmth pectin clathrate drop pill in order to solve existing colloid pectin bismuth preparation poor stability, shortcoming that bioavailability is low.
The application first is prepared into clathrate with colloidal bismmth pectin, and then is prepared into drop pill, and enclose and drop pill technology are united two into one, and brings into play the advantage of two aspects.
The colloidal bismmth pectin clathrate comprises active component and enclose material, and active component is colloidal bismmth pectin, and the enclose material is alpha-cyclodextrin, beta-schardinger dextrin-, hydroxyl beta-schardinger dextrin-, one or more of hydroxypropylβ-cyclodextrin.The part by weight of active component and enclose material is 3:2-2:3.
The preparation method of colloidal bismmth pectin clathrate comprises:
(1) in water or aquiferous ethanol medium, by a certain percentage, with colloidal bismmth pectin and alpha-cyclodextrin, beta-schardinger dextrin-, hydroxyl beta-schardinger dextrin-, one or more reactions of hydroxypropylβ-cyclodextrin, gained solution through extremely clarification of filtering with microporous membrane, is isolated clathrate from mixture; Or
(2) with solid form, with colloidal bismmth pectin and alpha-cyclodextrin, beta-schardinger dextrin-, hydroxyl beta-schardinger dextrin-, one or more reactions of hydroxypropylβ-cyclodextrin; Or
(3) colloidal bismmth pectin and alpha-cyclodextrin, beta-schardinger dextrin-, the hydroxyl beta-schardinger dextrin-, high energy milling is carried out in one or more reactions of hydroxypropylβ-cyclodextrin.
The above-mentioned colloidal bismmth pectin clathrate for preparing is crossed the 100-200 mesh sieve, be mixed into solid dispersion system with substrate and stabilizing agent, splash into the condensed fluid of 0-20 ℃ under 70 ± 5 ℃, adsorption condensing liquid, the drop pill drying, and get final product.
The substrate of indication of the present invention is selected from the two or more mixture such as polyethylene glycol 6000, Macrogol 4000, polyoxyethylene monostearate, sodium stearate, glycerin gelatine, poloxamer, stearic acid.
The applicant is surprised to find that, when substrate is selected polyethylene glycol 6000 and stearic compositions, and part by weight both is when being 60:40, and the drop pill that makes becomes ball, roundness best.
The stabilizing agent of indication of the present invention comprises that phosphatic PH buffering is right, as sodium hydrogen phosphate and sodium dihydrogen phosphate; Dipotassium hydrogen phosphate and potassium dihydrogen phosphate.
The condensed fluid of indication of the present invention comprises condensed fluid dimethicone, liquid paraffin, Oleum Camelliae, vegetable oil etc.
Metering of the present invention is weight.
Embodiment 1
The prescription of drop pill is (by weight):
Figure BDA00002947892600031
Preparation method:
1. prepare by the following method the colloidal bismmth pectin clathrate:
(1) in water or aquiferous ethanol medium, in proportion, with colloidal bismmth pectin and hydroxypropylβ-cyclodextrin reaction, gained solution through extremely clarification of filtering with microporous membrane, is isolated clathrate from mixture; Or
(2) with solid form, with colloidal bismmth pectin and hydroxypropylβ-cyclodextrin reaction; Or
(3) high energy milling is carried out in the reaction of colloidal bismmth pectin and hydroxypropylβ-cyclodextrin.
2. the colloidal bismmth pectin clathrate was pulverized the 100-200 mesh sieve; Polyethylene glycol 6000, stearic acid, dipotassium hydrogen phosphate and potassium dihydrogen phosphate ground and mixed is even, heating and melting on water-soluble, and mixing; The colloidal bismmth pectin clathrate is added in the fused mass of polyethylene glycol 6000, stearic acid, dipotassium hydrogen phosphate and potassium dihydrogen phosphate, mixing, in the impouring material fluid bath, kept 65-75 ℃ of temperature 10 minutes, above-mentioned medicinal liquid is splashed in the liquid paraffin of 0-20 ℃ and form drop pill, absorb condensed fluid, dry drop pill, packing.
Embodiment 2
The prescription of drop pill is (by weight):
Colloidal bismmth pectin clathrate (colloidal bismmth pectin: hydroxypropylβ-cyclodextrin is 2:3) 4g
Polyethylene glycol 6000 5g
Stearic acid 5g
Dipotassium hydrogen phosphate and potassium dihydrogen phosphate 0.2g
Liquid paraffin is appropriate.
Preparation method is with embodiment 1.
Embodiment 3
The prescription of drop pill is (by weight):
Figure BDA00002947892600041
Preparation method is with embodiment 1.
Embodiment 4
The prescription of drop pill is (by weight):
Figure BDA00002947892600042
Preparation method is with embodiment 1.
Embodiment 5
The prescription of drop pill is (by weight):
Colloidal bismmth pectin clathrate (colloidal bismmth pectin: hydroxypropylβ-cyclodextrin is 2:3) 4g
PLURONICS F87 6g
Stearic acid 4g
Dipotassium hydrogen phosphate and potassium dihydrogen phosphate 0.2g
Liquid paraffin is appropriate.
Preparation method is with embodiment 1.
Embodiment 6
The prescription of drop pill is (by weight):
Preparation method is with embodiment 1.
Matched group 1
The prescription of drop pill is (by weight):
Colloidal bismmth pectin clathrate (colloidal bismmth pectin: hydroxypropylβ-cyclodextrin is 2:3) 4g
Polyethylene glycol 6000 10g
Dipotassium hydrogen phosphate and potassium dihydrogen phosphate 0.2g
Condensed fluid is liquid paraffin.
Preparation method is with embodiment 1.
Matched group 2
The prescription of drop pill is (by weight):
Colloidal bismmth pectin clathrate (colloidal bismmth pectin: hydroxypropylβ-cyclodextrin is 2:3) 4g
Macrogol 4000 10g
Dipotassium hydrogen phosphate and potassium dihydrogen phosphate 0.2g
Condensed fluid is liquid paraffin.
Preparation method is with embodiment 1.
Matched group 3
The prescription of drop pill is (by weight):
Colloidal bismmth pectin clathrate (colloidal bismmth pectin: hydroxypropylβ-cyclodextrin is 2:3) 4g
Stearic acid 10g
Dipotassium hydrogen phosphate and potassium dihydrogen phosphate 0.2g
Condensed fluid is liquid paraffin.
Preparation method is with embodiment 1.
Matched group 4
The prescription of drop pill is (by weight):
Colloidal bismmth pectin clathrate (colloidal bismmth pectin: hydroxypropylβ-cyclodextrin is 2:3) 4g
PLURONICS F87 10g
Dipotassium hydrogen phosphate and potassium dihydrogen phosphate 0.2g
Condensed fluid is liquid paraffin.
Preparation method is with embodiment 1.
Colloidal bismmth pectin clathrate drop pill experimental result
The method of pressing Chinese Pharmacopoeia (2000 editions) detects smooth rounding rate and the dissolve scattered time limit of drop pill, the results are shown in Table 1.
Table 1
Group Smooth rounding rate (%) Dissolve scattered time limit (min)
Embodiment 1 98.64 2.1
Embodiment 2 90.41 2.9
Embodiment 3 91.32 2.6
Embodiment 4 85.46 2.8
Embodiment 5 83.92 2.2
Embodiment 6 86.14 2.5
Matched group 1 80.37 5.6
Matched group 2 77.83 6.0
Matched group 3 74.38 5.8
Matched group 4 76.98 5.7
Result shows, colloidal bismmth pectin clathrate drop pill provided by the invention meets Chinese Pharmacopoeia (2000 editions) about the regulation of drop pill.And according to polyethylene glycol 6000: the stearic acid part by weight is that the clathrate drop pill of 60:40 preparation has more excellent effect with respect to drop pill and the non-clathrate drop pill of non-this special ratios.

Claims (6)

1. drop pill, wherein active component is colloidal bismmth pectin.
2. drop pill as claimed in claim 1, wherein colloidal bismmth pectin is clathrate, the enclose material is alpha-cyclodextrin, beta-schardinger dextrin-, the hydroxyl beta-schardinger dextrin-, one or more of hydroxypropylβ-cyclodextrin, the part by weight of colloidal bismmth pectin and enclose material is 3:2-2:3.
3. drop pill as claimed in claim 2, wherein drop pill comprises the colloidal bismmth pectin clathrate, substrate, stabilizing agent.
4. drop pill as claimed in claim 3, its mesostroma comprise one or both the mixture such as polyethylene glycol 6000, Macrogol 4000, polyoxyethylene monostearate, sodium stearate, glycerin gelatine, poloxamer, stearic acid; Stabilizing agent comprises that phosphatic PH buffering is right, as sodium hydrogen phosphate and sodium dihydrogen phosphate; Dipotassium hydrogen phosphate and potassium dihydrogen phosphate.
5. drop pill as claimed in claim 4, wherein Basic compose is polyethylene glycol 6000 and stearic compositions, and part by weight both is 60:40.
6. drop pill as claimed in claim 4, wherein the prescription of drop pill is (by weight):
Colloidal bismmth pectin clathrate (colloidal bismmth pectin: hydroxypropylβ-cyclodextrin is 2:3) 4g
Polyethylene glycol 6000+stearic compositions (part by weight both is 60:40) 8g
Dipotassium hydrogen phosphate and potassium dihydrogen phosphate 0.2g
Condensed fluid is liquid paraffin.
CN201310092650.9A 2013-03-21 2013-03-21 Dropping pills containing colloidal bismuth pectin Active CN103142526B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310092650.9A CN103142526B (en) 2013-03-21 2013-03-21 Dropping pills containing colloidal bismuth pectin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310092650.9A CN103142526B (en) 2013-03-21 2013-03-21 Dropping pills containing colloidal bismuth pectin

Publications (2)

Publication Number Publication Date
CN103142526A true CN103142526A (en) 2013-06-12
CN103142526B CN103142526B (en) 2014-04-30

Family

ID=48541042

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310092650.9A Active CN103142526B (en) 2013-03-21 2013-03-21 Dropping pills containing colloidal bismuth pectin

Country Status (1)

Country Link
CN (1) CN103142526B (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
杨楠等: "砷、锑、铋类药物的应用历史和现状", 《化学进展》 *

Also Published As

Publication number Publication date
CN103142526B (en) 2014-04-30

Similar Documents

Publication Publication Date Title
KR102463682B1 (en) Viscosity-reducing excipient compounds for protein formulations
CN107098832B (en) A kind of honokiol derivative and the preparation method and application thereof
JPH0535129B2 (en)
CN101468138A (en) Gel patch for treating insomnia and method for preparing the same
CN105250231A (en) Drug combination containing etoricoxib and preparation method thereof
CN102614111A (en) Glucosamine gel and preparation method thereof
CN103142548B (en) Colloidal bismuth pectin capsule
CN103127015B (en) Alfacalcidol dropping pill and preparation method thereof
CN103142526B (en) Dropping pills containing colloidal bismuth pectin
CN106038584A (en) Colloidal bismuth pectin capsule preparation and preparation method thereof
CN103356492A (en) Tripterine pharmaceutical composition using albumin as pharmaceutical carrier
CN102697744B (en) Allose tablet excipient, medicinal tablet and method for preparing medicinal tablet
US11260025B1 (en) In situ gelling composition as a pH-selective and mucoadhesive sustained release drug delivery system
CN103083269B (en) Dropping pills containing mannose ester and preparation method thereof
CN103110636B (en) Paracetamol and caffeine dropping pill and preparation method thereof
CN103110629B (en) Compound phenol caplets dropping pills and preparation method thereof
CN103142523B (en) Dropping pills containing etoposide
CN108136210A (en) composition containing tannin
CN103127021A (en) Vitamin c dropping pill
CN104971070A (en) Oral nano composition of ticagrelor
CN102028836A (en) Medicine dropping pill used for clearing heat and diminishing swelling and preparation method thereof
CN104352556A (en) Radix sophorae flavescentis total alkaloids dropping pill
CN104147436B (en) A kind of coix seed oil oral administration nanometer grain and preparation method thereof
CN103127027B (en) Polysaccharide sulphate dropping pill
CN106619580A (en) Antipyretic-analgesic externally-used patch prepared from high polymer material

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 266103 Qingdao economic and Technological Development Zone, unity Road, No. 3601, Shandong

Applicant after: Qingdao Zhengda Haier Pharmaceutical Co.,Ltd.

Address before: 266103 Haier Road, Shandong, Qingdao, No. 1

Applicant before: Qingdao Zhengda Haier Pharmaceutical Co.,Ltd.

CB02 Change of applicant information
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: 266103 3601 Tuen Jie Road, Qingdao economic and Technological Development Zone, Shandong

Patentee after: CP PHARMACEUTICAL (QINGDAO) Co.,Ltd.

Address before: 266103 3601 Tuen Jie Road, Qingdao economic and Technological Development Zone, Shandong

Patentee before: Qingdao Zhengda Haier Pharmaceutical Co.,Ltd.

CP01 Change in the name or title of a patent holder
CP03 Change of name, title or address

Address after: No.3601 Tuanjie Road, Qingdao Economic and Technological Development Zone, Shandong Province 266426

Patentee after: Qingdao Guoxin Pharmaceutical Co.,Ltd.

Country or region after: China

Address before: No. 3601 Tuanjie Road, Qingdao Economic and Technological Development Zone, Shandong Province

Patentee before: CP PHARMACEUTICAL (QINGDAO) Co.,Ltd.

Country or region before: China

CP03 Change of name, title or address